KR102097663B1 - 눈 질병 및 질환을 위한 조성물 및 치료 - Google Patents

눈 질병 및 질환을 위한 조성물 및 치료 Download PDF

Info

Publication number
KR102097663B1
KR102097663B1 KR1020157004782A KR20157004782A KR102097663B1 KR 102097663 B1 KR102097663 B1 KR 102097663B1 KR 1020157004782 A KR1020157004782 A KR 1020157004782A KR 20157004782 A KR20157004782 A KR 20157004782A KR 102097663 B1 KR102097663 B1 KR 102097663B1
Authority
KR
South Korea
Prior art keywords
progesterone
pharmaceutical composition
composition
eye
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157004782A
Other languages
English (en)
Korean (ko)
Other versions
KR20150038311A (ko
Inventor
웨이-웨이 창
케니스 소여
Original Assignee
글리아, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리아, 엘엘씨 filed Critical 글리아, 엘엘씨
Publication of KR20150038311A publication Critical patent/KR20150038311A/ko
Application granted granted Critical
Publication of KR102097663B1 publication Critical patent/KR102097663B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020157004782A 2012-07-27 2013-07-26 눈 질병 및 질환을 위한 조성물 및 치료 Active KR102097663B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US61/676,530 2012-07-27
US201361756321P 2013-01-24 2013-01-24
US61/756,321 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Publications (2)

Publication Number Publication Date
KR20150038311A KR20150038311A (ko) 2015-04-08
KR102097663B1 true KR102097663B1 (ko) 2020-04-06

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157004782A Active KR102097663B1 (ko) 2012-07-27 2013-07-26 눈 질병 및 질환을 위한 조성물 및 치료

Country Status (20)

Country Link
US (2) US20150216877A1 (enExample)
EP (1) EP2877184B1 (enExample)
JP (1) JP6209777B2 (enExample)
KR (1) KR102097663B1 (enExample)
CN (2) CN104661663A (enExample)
AU (1) AU2013295645B2 (enExample)
BR (1) BR112015001847A8 (enExample)
CA (1) CA2880027C (enExample)
DK (1) DK2877184T3 (enExample)
ES (1) ES2759781T3 (enExample)
HU (1) HUE046963T2 (enExample)
IL (1) IL236920B (enExample)
IN (1) IN2015DN00542A (enExample)
MX (1) MX362185B (enExample)
NZ (1) NZ704247A (enExample)
PL (1) PL2877184T3 (enExample)
PT (1) PT2877184T (enExample)
SM (1) SMT201900678T1 (enExample)
WO (1) WO2014018856A1 (enExample)
ZA (1) ZA201500561B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2909490C (en) 2013-03-15 2021-07-13 Glia, Llc Cranial delivery of pharmaceuticals
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016014419A1 (en) 2014-07-21 2016-01-28 Glia, Llc Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
CA3167771A1 (en) * 2020-02-12 2021-08-19 Glia, Llc Progesterone combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028910A1 (en) 2007-10-08 2012-02-02 Jean-Philippe Combal Storage-stable aqueous ophthalmic formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028910A1 (en) 2007-10-08 2012-02-02 Jean-Philippe Combal Storage-stable aqueous ophthalmic formulations

Also Published As

Publication number Publication date
SMT201900678T1 (it) 2020-03-13
CA2880027C (en) 2021-12-07
BR112015001847A2 (pt) 2017-07-04
CN104661663A (zh) 2015-05-27
AU2013295645B2 (en) 2017-08-24
EP2877184A4 (en) 2016-03-30
PT2877184T (pt) 2019-12-02
AU2013295645A1 (en) 2015-02-05
HK1210968A1 (en) 2016-05-13
DK2877184T3 (da) 2019-12-09
KR20150038311A (ko) 2015-04-08
IN2015DN00542A (enExample) 2015-06-26
CA2880027A1 (en) 2014-01-30
EP2877184A1 (en) 2015-06-03
EP2877184B1 (en) 2019-09-04
JP2015524434A (ja) 2015-08-24
US20170189413A1 (en) 2017-07-06
US20150216877A1 (en) 2015-08-06
US9925201B2 (en) 2018-03-27
BR112015001847A8 (pt) 2021-09-08
CN107595857A (zh) 2018-01-19
ZA201500561B (en) 2016-04-28
PL2877184T3 (pl) 2020-04-30
JP6209777B2 (ja) 2017-10-11
NZ704247A (en) 2018-04-27
IL236920B (en) 2018-06-28
WO2014018856A1 (en) 2014-01-30
HUE046963T2 (hu) 2020-04-28
MX2015001250A (es) 2015-10-22
MX362185B (es) 2019-01-08
ES2759781T3 (es) 2020-05-12

Similar Documents

Publication Publication Date Title
KR102097663B1 (ko) 눈 질병 및 질환을 위한 조성물 및 치료
US20210008079A1 (en) Treatment for dry eye
CN111182893A (zh) 包含f6h8的眼用组合物
KR20180042348A (ko) 안과 약물의 정량적 안와주위 적용
AU2017357755B2 (en) Formulations for the treatment of ocular surface diseases and related methods
CN111372564B (zh) 用于治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
KR20220011691A (ko) 안 질환의 치료
US20250041212A1 (en) Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
EP2424535B1 (en) Methods and compositions for treating dry eye
TWI632913B (zh) 用於眼部疾病或異常之組合物及其治療方法
CN102018656A (zh) 含有效成分拉坦前列素的眼用凝胶剂及其制备方法
HK1210968B (en) Compositions and treatment for eye diseases and disorders
HK40028751A (en) Ophthalmic compositions comprising f6h8
CN105214092A (zh) 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7